-
Something wrong with this record ?
Identification of novel dithiocarbamate-copper complexes targeting p97/NPL4 pathway in cancer cells
M. Loffelmann, Z. Škrott, D. Majera, P. Štarha, V. Kryštof, M. Mistrík
Language English Country France
Document type Journal Article
- MeSH
- Disulfiram pharmacology MeSH
- Copper * pharmacology MeSH
- Neoplasms * drug therapy MeSH
- Proteasome Endopeptidase Complex MeSH
- Proteins metabolism MeSH
- Ubiquitin metabolism MeSH
- Publication type
- Journal Article MeSH
Dithiocarbamates (DTCs) are simple organic compounds with many applications in industry and medicine. They are potent metal chelators forming complexes with various metal ions, including copper. Recently, bis(diethyldithiocarbamate)-copper complex (CuET) has been identified as a metabolic product of the anti-alcoholic drug Antabuse (disulfiram, DSF), standing behind DSF's reported anticancer activity. Mechanistically, CuET in cells causes aggregation of NPL4 protein, an essential cofactor of the p97 segregase, an integral part of the ubiquitin-proteasome system. The malfunction of p97/NPL4 caused by CuET leads to proteotoxic stress accompanied by heat shock and unfolded protein responses and cancer cell death. However, it is not known whether the NPL4 inhibition is unique for CuET or whether it is shared with other dithiocarbamate-copper complexes. Thus, we tested 20 DTCs-copper complexes in this work for their ability to target and aggregate NPL4 protein. Surprisingly, we have found that certain potency against NPL4 is relatively common for structurally different DTCs-copper complexes, as thirteen compounds scored in the cellular NPL4 aggregation assay. These compounds also shared typical cellular phenotypes reported previously for CuET, including the NPL4/p97 proteins immobilization, accumulation of polyubiquitinated proteins, the unfolded protein, and the heat shock responses. Moreover, the active complexes were also toxic to cancer cells (the most potent in the nanomolar range), and we have found a strong positive correlation between NPL4 aggregation and cytotoxicity, confirming NPL4 as a relevant target. These results show the widespread potency of DTCs-copper complexes to target NPL4 with subsequent induction of lethal proteotoxic stress in cancer cells with implications for drug development.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000299
- 003
- CZ-PrNML
- 005
- 20240213093046.0
- 007
- ta
- 008
- 240109e20230904fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2023.115790 $2 doi
- 035 __
- $a (PubMed)37690264
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Loffelmann, Martin $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 1333/5, Olomouc, 779 00, Czech Republic
- 245 10
- $a Identification of novel dithiocarbamate-copper complexes targeting p97/NPL4 pathway in cancer cells / $c M. Loffelmann, Z. Škrott, D. Majera, P. Štarha, V. Kryštof, M. Mistrík
- 520 9_
- $a Dithiocarbamates (DTCs) are simple organic compounds with many applications in industry and medicine. They are potent metal chelators forming complexes with various metal ions, including copper. Recently, bis(diethyldithiocarbamate)-copper complex (CuET) has been identified as a metabolic product of the anti-alcoholic drug Antabuse (disulfiram, DSF), standing behind DSF's reported anticancer activity. Mechanistically, CuET in cells causes aggregation of NPL4 protein, an essential cofactor of the p97 segregase, an integral part of the ubiquitin-proteasome system. The malfunction of p97/NPL4 caused by CuET leads to proteotoxic stress accompanied by heat shock and unfolded protein responses and cancer cell death. However, it is not known whether the NPL4 inhibition is unique for CuET or whether it is shared with other dithiocarbamate-copper complexes. Thus, we tested 20 DTCs-copper complexes in this work for their ability to target and aggregate NPL4 protein. Surprisingly, we have found that certain potency against NPL4 is relatively common for structurally different DTCs-copper complexes, as thirteen compounds scored in the cellular NPL4 aggregation assay. These compounds also shared typical cellular phenotypes reported previously for CuET, including the NPL4/p97 proteins immobilization, accumulation of polyubiquitinated proteins, the unfolded protein, and the heat shock responses. Moreover, the active complexes were also toxic to cancer cells (the most potent in the nanomolar range), and we have found a strong positive correlation between NPL4 aggregation and cytotoxicity, confirming NPL4 as a relevant target. These results show the widespread potency of DTCs-copper complexes to target NPL4 with subsequent induction of lethal proteotoxic stress in cancer cells with implications for drug development.
- 650 12
- $a měď $x farmakologie $7 D003300
- 650 _2
- $a proteiny $x metabolismus $7 D011506
- 650 _2
- $a disulfiram $x farmakologie $7 D004221
- 650 _2
- $a ubikvitin $x metabolismus $7 D025801
- 650 _2
- $a proteasomový endopeptidasový komplex $7 D046988
- 650 12
- $a nádory $x farmakoterapie $7 D009369
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Škrott, Zdeněk $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 1333/5, Olomouc, 779 00, Czech Republic
- 700 1_
- $a Majera, Dušana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 1333/5, Olomouc, 779 00, Czech Republic
- 700 1_
- $a Štarha, Pavel $u Department of Inorganic Chemistry, Faculty of Science, Palacky University Olomouc, 17. listopadu 1192/12, Olomouc, 779 00, Czech Republic
- 700 1_
- $a Kryštof, Vladimír $u Department of Experimental Biology, Faculty of Science, Palacky University Olomouc, Slechtitelu 27, Olomouc, 783 71, Czech Republic. Electronic address: vladimir.krystof@upol.cz
- 700 1_
- $a Mistrík, Martin $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 1333/5, Olomouc, 779 00, Czech Republic. Electronic address: martin.mistrik@upol.cz
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 261 (20230904), s. 115790
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37690264 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093043 $b ABA008
- 999 __
- $a ok $b bmc $g 2049141 $s 1209993
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 261 $c - $d 115790 $e 20230904 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20240109